Histology-Agnostic Biomarkers in Advanced Gastrointestinal Malignancies

Download these slides from our 2020 ASCO-GI live satellite symposium on histology-agnostic biomarkers in advanced GI cancers including MMR/MSI and NTRK fusions.
Pashtoon Kasi, MD
John L. Marshall, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.36 MB
Released: January 23, 2020


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Array BioPharma Inc.
Bayer HealthCare Pharmaceuticals Inc.
Merck Sharp & Dohme Corp.

Related Content

Downloadable slideset with key data from the 2020 ESMO Virtual Congress created by Clinical Care Options (CCO)

Yelena Y. Janjigian, MD Joyce O'Shaughnessy, MD Elizabeth R. Plimack, MD, MS person default Vamsidhar Velcheti, MD Released: October 23, 2020

From Clinical Care Options (CCO), Richard Finn, MD, discusses optimal transitioning of patients with HCC from locoregional to systemic therapy

Richard Finn, MD Released: October 20, 2020

In this commentary from Clinical Care Options (CCO), experts discuss second-line treatment after atezolizumab plus bevacizumab for patients with advanced HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: October 1, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.